Rare Disease Genetic Testing Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Rare Disease Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Neurological Disease, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders (CVDs), Dermatology Disease, Others), By Speciality (Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests), By Technology (Next-Generation Sequencing (NGS), Whole Exome Sequencing, Whole Genome Sequencing, Array Technology, PCR-based Testing, FISH, Sanger Sequencing, Karyotyping), By End User (Research Laboratories & CROs, Hospitals & Clinics, Diagnostic Laboratories), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Rare Disease Genetic Testing Market is projected to expand significantly, from USD 1.11 Billion in 2025 to USD 1.83 Billion by 2031, exhibiting an 8.69% Compound Annual Growth Rate. This market encompasses specialized diagnostic services and assays designed to analyze genetic material to pinpoint mutations linked to low-prevalence medical conditions. The primary catalysts for this growth are the swift decrease in genomic sequencing expenses and the pressing clinical need to provide definitive diagnoses for patients facing complex and lengthy diagnostic journeys.
The demand for these services is further bolstered by the vast number of rare and genetic diseases identified globally, exceeding 10,000 distinct types as of 2024, according to Global Genes. Despite this substantial growth potential, the market's progress is frequently hampered by considerable hurdles concerning reimbursement and coverage policies. Inconsistent payment structures and strict payer requirements often lead to denied claims or prohibitive out-of-pocket expenses for patients, thereby limiting access to essential diagnostic resources and decelerating the widespread commercial adoption of advanced testing panels.
Market Driver
The Global Rare Disease Genetic Testing Market is primarily driven by two key factors: substantial reductions in genomic sequencing costs and rapid advancements in Next-Generation Sequencing (NGS) technologies. These technological progress points have effectively removed financial obstacles, transforming high-throughput sequencing from a niche luxury into a standard diagnostic procedure. This shift is exemplified by the introduction of ultra-low-cost platforms, such as Ultima Genomics' UG 100 sequencer, launched in February 2024, which can deliver a $100 genome. This newfound affordability accelerates the widespread adoption of whole-genome sequencing (WGS), consequently boosting the global volume of processed samples.
This industrial-scale expansion is further demonstrated by major research centers like Regeneron's Genetics Center, which, by September 2024, had successfully sequenced over 2.5 million human exomes, indicating massive capacity growth in the sector. Concurrently, the market benefits from increased R&D investment in orphan drugs and companion diagnostics, stimulated by supportive government regulations. As regulatory agencies encourage the development of treatments for low-prevalence conditions, pharmaceutical companies are increasingly using genetic testing to identify rare mutations and effectively stratify patients for clinical trials. This is underscored by the U.S. FDA's January 2025 report on 2024 drug approvals, which showed that 52% of all novel drug approvals were for rare or orphan diseases, highlighting the essential role of robust companion diagnostics and genetic testing in delivering precision medicine to rare disease patients.
Market Challenge
The primary obstacle impeding the growth of the Global Rare Disease Genetic Testing Market consists of restrictive reimbursement policies and inconsistent coverage criteria. Insurers often categorize advanced genomic assays, including Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), as experimental or investigational. This classification typically stems from a perceived absence of adequate clinical utility data, frequently leading to outright claim denials or the imposition of strict prior authorization prerequisites.
These challenges impose substantial financial risks on diagnostic laboratories and result in prohibitive out-of-pocket costs for patients. Such administrative barriers effectively disconnect the availability of advanced testing from patient access, causing healthcare providers to be reluctant in ordering comprehensive genetic panels that could resolve complex diagnostic journeys. The operational friction created by these coverage disputes significantly hinders commercial adoption, with the American Medical Association reporting in 2024 that 94% of physicians experienced delays in patient care due to prior authorization requirements, a systemic issue particularly impacting time-sensitive genetic diagnoses. Consequently, the market's revenue potential is constrained not by a lack of demand, but by the uncertainty surrounding payment for these high-value diagnostic services.
Market Trends
The integration of artificial intelligence (AI) into variant analysis is profoundly transforming the market by addressing data interpretation bottlenecks that persist despite advancements in sequencing technology. As the volume of genomic data grows exponentially, laboratories are increasingly adopting machine learning algorithms to automate the classification of pathogenicity and prioritize causal variants, thereby mitigating the pervasive challenge of variants of uncertain significance (VUS). This technological evolution substantially shortens diagnostic turnaround times and improves clinical precision, particularly for complex genetic cases.
The rapid maturation of computational tools essential for accurate genetic interpretation is evident in developments like Google DeepMind's AlphaFold 3, which, as of May 2024, demonstrated a 50% improvement in predicting protein-DNA interactions compared to specialized tools. Concurrently, the market is witnessing a significant structural shift towards proactive population health management through the expansion of genomic newborn screening panels. Public health initiatives are increasingly integrating or entirely replacing traditional biochemical assays with genomic sequencing to screen infants for a much wider array of treatable conditions. This trend stimulates market growth by requiring high-volume sequencing workflows and the development of specialized panels tailored for early disease detection, exemplified by Genomics England's October 2024 pilot program to screen newborns for over 200 rare genetic conditions.
Key Market Players
* Centogene N.V.
* Invitae Corp.
* 3billion, Inc.
* Eurofins Scientific SE
* Strand Life Sciences Pvt Ltd
* Ambry Genetics Corp.
* Perkin Elmer, Inc.
* Realm IDX, Inc.
* Macrogen, Inc.
* Baylor Miraca Genetics Laboratories, LLC
Report Scope
In this report, the Global Rare Disease Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Rare Disease Genetic Testing Market, By Disease Type
* Neurological Disease
* Immunological Disorders
* Hematology Diseases
* Endocrine & Metabolism Diseases
* Cancer
* Musculoskeletal Disorders
* Cardiovascular Disorders (CVDs)
* Dermatology Disease
* Others
# Rare Disease Genetic Testing Market, By Speciality
* Molecular Genetic Tests
* Chromosomal Genetic Tests
* Biochemical Genetic Tests
# Rare Disease Genetic Testing Market, By Technology
* Next-Generation Sequencing (NGS)
* Whole Exome Sequencing
* Whole Genome Sequencing
* Array Technology
* PCR-based Testing
* FISH
* Sanger Sequencing
* Karyotyping
# Rare Disease Genetic Testing Market, By End User
* Research Laboratories & CROs
* Hospitals & Clinics
* Diagnostic Laboratories
# Rare Disease Genetic Testing Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Rare Disease Genetic Testing Market.
Available Customizations:
Global Rare Disease Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Rare Disease Genetic Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Neurological Disease, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders (CVDs), Dermatology Disease, Others)
5.2.2. By Speciality (Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests)
5.2.3. By Technology (Next-Generation Sequencing (NGS), Whole Exome Sequencing, Whole Genome Sequencing, Array Technology, PCR-based Testing, FISH, Sanger Sequencing, Karyotyping)
5.2.4. By End User (Research Laboratories & CROs, Hospitals & Clinics, Diagnostic Laboratories)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Rare Disease Genetic Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Speciality
6.2.3. By Technology
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Rare Disease Genetic Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Speciality
6.3.1.2.3. By Technology
6.3.1.2.4. By End User
6.3.2. Canada Rare Disease Genetic Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Speciality
6.3.2.2.3. By Technology
6.3.2.2.4. By End User
6.3.3. Mexico Rare Disease Genetic Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Speciality
6.3.3.2.3. By Technology
6.3.3.2.4. By End User
7. Europe Rare Disease Genetic Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Speciality
7.2.3. By Technology
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Rare Disease Genetic Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Speciality
7.3.1.2.3. By Technology
7.3.1.2.4. By End User
7.3.2. France Rare Disease Genetic Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Speciality
7.3.2.2.3. By Technology
7.3.2.2.4. By End User
7.3.3. United Kingdom Rare Disease Genetic Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Speciality
7.3.3.2.3. By Technology
7.3.3.2.4. By End User
7.3.4. Italy Rare Disease Genetic Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Speciality
7.3.4.2.3. By Technology
7.3.4.2.4. By End User
7.3.5. Spain Rare Disease Genetic Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Speciality
7.3.5.2.3. By Technology
7.3.5.2.4. By End User
8. Asia Pacific Rare Disease Genetic Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Speciality
8.2.3. By Technology
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Rare Disease Genetic Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Speciality
8.3.1.2.3. By Technology
8.3.1.2.4. By End User
8.3.2. India Rare Disease Genetic Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Speciality
8.3.2.2.3. By Technology
8.3.2.2.4. By End User
8.3.3. Japan Rare Disease Genetic Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Speciality
8.3.3.2.3. By Technology
8.3.3.2.4. By End User
8.3.4. South Korea Rare Disease Genetic Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Speciality
8.3.4.2.3. By Technology
8.3.4.2.4. By End User
8.3.5. Australia Rare Disease Genetic Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Speciality
8.3.5.2.3. By Technology
8.3.5.2.4. By End User
9. Middle East & Africa Rare Disease Genetic Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Speciality
9.2.3. By Technology
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Rare Disease Genetic Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Speciality
9.3.1.2.3. By Technology
9.3.1.2.4. By End User
9.3.2. UAE Rare Disease Genetic Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Speciality
9.3.2.2.3. By Technology
9.3.2.2.4. By End User
9.3.3. South Africa Rare Disease Genetic Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Speciality
9.3.3.2.3. By Technology
9.3.3.2.4. By End User
10. South America Rare Disease Genetic Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Speciality
10.2.3. By Technology
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Rare Disease Genetic Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Speciality
10.3.1.2.3. By Technology
10.3.1.2.4. By End User
10.3.2. Colombia Rare Disease Genetic Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Speciality
10.3.2.2.3. By Technology
10.3.2.2.4. By End User
10.3.3. Argentina Rare Disease Genetic Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Speciality
10.3.3.2.3. By Technology
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Rare Disease Genetic Testing Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Centogene N.V.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Invitae Corp.
15.3. 3billion, Inc.
15.4. Eurofins Scientific SE
15.5. Strand Life Sciences Pvt Ltd
15.6. Ambry Genetics Corp.
15.7. Perkin Elmer, Inc.
15.8. Realm IDX, Inc.
15.9. Macrogen, Inc.
15.10. Baylor Miraca Genetics Laboratories, LLC
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們